Loading...
Market
What will be the market share of combination vaccines including Moderna's mRNA-1083 by end of 2025?
4
Resolution / Starting Odds
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Market analysis reports, company earnings reports
Story
Moderna's mRNA-1083 Combo COVID-19 and Flu Vaccine Shows Strong Phase 3 Results
Jun 10, 2024, 01:10 PM
Moderna announced that its investigational combination vaccine, mRNA-1083, which targets both COVID-19 and seasonal influenza, has shown positive results in a Phase 3 late-stage trial. The vaccine generated a stronger immune response in adults aged 50 and over compared to separate shots for each virus. The combination vaccine was found to be more effective than existing standalone vaccines, including Moderna's own Spikevax. The success of the trial brings Moderna closer to potentially filing for regulatory approval, with market availability anticipated as early as fall 2025. Moderna CEO Stephane Bancel highlighted the convenience and potential benefits of combination vaccines, especially in the context of labor shortages in healthcare.
View original story
Similar markets
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Under 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Over 60% • 25%
Under $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Below 20% market share • 33%
20-40% market share • 34%
Above 40% market share • 33%
More than 20% • 50%
20% or less • 50%
Increased Moderna market share • 33%
No significant change • 34%
Decreased Pfizer/BioNTech market share • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Moderna gains highest market share • 33%
Pfizer retains highest market share • 33%
BioNTech gains highest market share • 33%
More than GSK and Pfizer combined • 50%
Less than GSK and Pfizer combined • 50%
Less than 50 million • 25%
50 to 100 million • 25%
100 to 200 million • 25%
More than 200 million • 25%